This is an open-label study of weight-adjusted 1000 mg tideglusib, once daily for 52 weeks with an optional further 32-week extended access period in children and adolescents with a diagnosis of Congenital DM1 who participated in the AMO-02-MD-2-003 study or children and adolescents with either Congenital or Childhood Onset DM1 who are treatment naïve.
This is an open-label phase 2/3 study for children and adolescents with Congenital Myotonic Dystrophy (Congenital DM1) who participated in the preceding AMO-02-MD-2-003 study or children and adolescents with either Congenital or Childhood Onset DM1 who are treatment naïve.